5 things to know before the market opens Thursday
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Good morning. We’re minutes away…
Tariffs and Iran war threaten India’s $100 billion garments export goal
Hello, this is Priyanka Salve, writing to you from Singapore. Welcome to the latest edition of “Inside India”…
Trump prepares pharmaceutical tariffs of up to 100%
The Trump administration is preparing to impose new tariffs on branded drugs from pharmaceutical companies that have not…
Novo Nordisk launches Wegovy subscription for GLP-1 obesity drugs
Wegovy semaglutide tablets. Michael Siluk | Universal Images Group | Getty Images Novo Nordisk on Tuesday launched a…
Stocks soar on hopes of Iran war resolution — plus, Lilly takes a big swing in sleep disorders
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
Eli Lilly reaches deal to bring AI-developed drugs to global market
A drone view shows the Eli Lilly logo on the company’s office in San Diego, California, Nov. 21,…
Eli Lilly’s obesity drug retatrutide clears late-stage diabetes trial
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike…
Stopping GLP-1s raises cardiovascular risks: study
Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. Hollie Adams | Reuters…
Novo Nordisk sues Hims & Hers over compounded obesity drugs
Novo Nordisk on Monday said it is suing online telehealth provider Hims & Hers for mass marketing cheaper,…
Hims & Hers announces Wegovy pill copy; Novo Nordisk vows legal action
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark,…
White House launches direct to consumer drug site
President Donald Trump makes an announcement from the Oval Office at the White House in Washington, Nov. 6,…
Eli Lilly (LLY) earnings Q4 2025
Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand…